GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Phreesia Inc (NYSE:PHR) » Definitions » Sloan Ratio %

Phreesia (Phreesia) Sloan Ratio % : -17.51% (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Phreesia Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Phreesia's Sloan Ratio for the quarter that ended in Jan. 2024 was -17.51%.

As of Jan. 2024, Phreesia has a Sloan Ratio of -17.51%, indicating there is a warning stage of accrual build up.


Phreesia Sloan Ratio % Historical Data

The historical data trend for Phreesia's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phreesia Sloan Ratio % Chart

Phreesia Annual Data
Trend Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Sloan Ratio %
Get a 7-Day Free Trial -5.54 -1.56 4.40 -16.17 -17.51

Phreesia Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.17 -18.94 -18.72 -16.27 -17.51

Competitive Comparison of Phreesia's Sloan Ratio %

For the Health Information Services subindustry, Phreesia's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phreesia's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Phreesia's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Phreesia's Sloan Ratio % falls into.



Phreesia Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Phreesia's Sloan Ratio for the fiscal year that ended in Jan. 2024 is calculated as

Sloan Ratio=(Net Income (A: Jan. 2024 )-Cash Flow from Operations (A: Jan. 2024 )
-Cash Flow from Investing (A: Jan. 2024 ))/Total Assets (A: Jan. 2024 )
=(-136.885--32.378
--39.67)/370.326
=-17.51%

Phreesia's Sloan Ratio for the quarter that ended in Jan. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jan. 2024 )
=(-136.885--32.378
--39.67)/370.326
=-17.51%

Phreesia's Net Income for the trailing twelve months (TTM) ended in Jan. 2024 was -37.531 (Apr. 2023 ) + -36.767 (Jul. 2023 ) + -31.941 (Oct. 2023 ) + -30.646 (Jan. 2024 ) = $-136.9 Mil.
Phreesia's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2024 was -13.659 (Apr. 2023 ) + -9.331 (Jul. 2023 ) + -6.31 (Oct. 2023 ) + -3.078 (Jan. 2024 ) = $-32.4 Mil.
Phreesia's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2024 was -6.079 (Apr. 2023 ) + -9.716 (Jul. 2023 ) + -15.717 (Oct. 2023 ) + -8.158 (Jan. 2024 ) = $-39.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phreesia  (NYSE:PHR) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jan. 2024, Phreesia has a Sloan Ratio of -17.51%, indicating there is a warning stage of accrual build up.


Phreesia Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Phreesia's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Phreesia (Phreesia) Business Description

Traded in Other Exchanges
Address
1521 Concord Pike, Suite 301 PMB 221, Wilmington, DE, USA, 19803
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
Executives
Balaji Gandhi officer: Chief Financial Officer PHREESIA, INC., 1521 CONCORD PIKE, SUITE 301, PMB 221, WILMINGTON DE 19803
Allison C Hoffman officer: General Counsel & Secretary 315 EAST 68TH STREET, NEW YORK NY 10065
Amy Beth Vanduyn officer: SVP, Human Resources C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Chaim Indig director, officer: Chief Executive Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Michael J. Davidoff officer: See Remarks C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
David Linetsky officer: SVP, Life Sciences C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Evan Roberts officer: Chief Operating Officer C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Janet Gunzburg officer: Principal Accounting Officer BANKRATE, INC., 477 MADISON AVENUE, SUITE 430, NEW YORK NY 10022
Lisa Egbuonu-davis director C/O OMEGA HEALTHCARE INVESTORS, INC., 303 INTERNATIONAL CIRCLE, SUITE 200, HUNT VALLEY MD 21030
Gillian Munson director C/O XO GROUP INC., 195 BROADWAY, 25TH FLOOR, NEW YORK NY 10007
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Randy Rasmussen officer: Chief Financial Officer PHREESIA, INC., 434 FAYETTEVILLE ST., SUITE 1400, RALEIGH NC 27601
Ramin Sayar director 305 MAIN STREET, REDWOOD CITY CA 94063
Michael Weintraub director C/O PHREESIA, INC., 432 PARK AVENUE S., 12TH FLOOR, NEW YORK NY 10016
Edward L Cahill 10 percent owner C/O HLM VENTURE PARTNERS, 800 SOUTH STREET, SUITE 200, WALTHAM MA 02453